Metrics as of 10/13/2026, 06:46 PM (Berlin time), refresh in progress.
Ascendis Pharma A/S Stock
Ascendis Pharma A/S
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Denmark
- CEO
- Jan Moller Mikkelsen
- Employees
- 1,189
- Market cap
- $13.9 B
- IPO
- 28/01/2015
Ascendis Pharma A/S is a biopharmaceutical enterprise operating within the Healthcare sector and the Biotechnology industry. The company is headquartered in Hellerup, Denmark. Founded in 2006, the firm maintains its corporate headquarters in this Danish location. With 1,189 employees, the enterprise is dedicated to…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Ascendis Pharma A/S stock: price history
1D
-1.7%
1W
-1.3%
1M
-15.3%
6M
-10.7%
YTD
+4.7%
1Y
+7.1%
2Y
+73.2%
5Y
+31.9%
10Y
+992.0%
Next earnings date
Next earnings date
11/11/2026 (in 25 days)
Volatility around earnings
~30% stronger price swings than usual
Ask the agents about Ascendis Pharma A/S
Analyst assessment of Ascendis Pharma A/S
PRICE TARGET LOW
US$273.00
CONSENSUS
US$317.42
MEDIAN
US$326.00
PRICE TARGET HIGH
US$344.00
0
STRONG BUY
24
BUY
2
HOLD
0
SELL
0
STRONG SELL
26
TOTAL · Buy
As of: 25/09/2026
Ascendis Pharma A/S stock metrics
P/E
16.48
P/B
8.93
EV/EBITDA
153.85
RETURN ON EQUITY
14.7%
NET MARGIN
61.0%
DEBT/EQUITY
0.31
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
99.1%
FLOAT SHARES
61,558,988
AVG. DAILY VOLUME (30D)
863,429
Insider transactions (SEC)
Bodenhoff Mads
Bodenhoff Mads
HOLTUG LARS
BIENAIME JEAN JACQUES
BIENAIME JEAN JACQUES
Institutional holders
Comparable stocks
Frequently asked questions about Ascendis Pharma A/S stock
What does Ascendis Pharma A/S do?
Ascendis Pharma A/S is a company in the Healthcare sector, Biotechnology industry, headquartered in Denmark.
The CEO is Jan Moller Mikkelsen, the company employs around 1,189 people.
The IPO was on 28/01/2015; the stock trades on NASDAQ under the ticker ASND.
What do analysts say about Ascendis Pharma A/S stock?
26 analysts rate the stock, the consensus is Buy (as of 25/09/2026).
The average price target is US$317.42, ranging from US$273.00 to US$344.00, with a median of US$326.00.
This is an external assessment, not a statement by Market Jury.
When does Ascendis Pharma A/S report next?
The next earnings date is 11/11/2026.
Around past earnings, price swings were roughly 30% stronger than usual.
Does Ascendis Pharma A/S pay a dividend?
No, Ascendis Pharma A/S currently does not pay a dividend.
Which stocks are comparable to Ascendis Pharma A/S?
Comparable stocks include Genmab A/S, Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, argenx, Revolution Medicines, BeOne Medicines and Incyte.
How can I get Ascendis Pharma A/S stock analyzed?
Clicking "Analyze stock" lets five strategies assess Ascendis Pharma A/S against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.